Lantern Pharma Inc.
LTRN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $16 | $12 | $9 | $8 |
| G&A Expenses | $6 | $6 | $6 | $5 |
| SG&A Expenses | $6 | $6 | $6 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $22 | $18 | $14 | $13 |
| Operating Income | -$22 | -$18 | -$14 | -$13 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $2 | $0 | $0 |
| Pre-Tax Income | -$21 | -$16 | -$14 | -$12 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$21 | -$16 | -$14 | -$12 |
| % Margin | – | – | – | – |
| EPS | -1,930.92 | -1.47 | -1.31 | -1.13 |
| % Growth | -131,255.1% | -12.2% | -15.9% | – |
| EPS Diluted | -1,930.92 | -1.47 | -1.31 | -1.13 |
| Weighted Avg Shares Out | 11 | 11 | 11 | 11 |
| Weighted Avg Shares Out Dil | 11 | 11 | 11 | 11 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$22 | -$16 | -$14 | -$13 |
| % Margin | – | – | – | – |